vs
Canopy Growth Corp（CGC）与Niagen Bioscience, Inc.（NAGE）财务数据对比。点击上方公司名可切换其他公司
Canopy Growth Corp的季度营收约是Niagen Bioscience, Inc.的1.6倍（$54.4M vs $33.8M）。Niagen Bioscience, Inc.净利率更高（12.2% vs -84.0%，领先96.2%）。Niagen Bioscience, Inc.同比增速更快（16.2% vs -0.3%）。过去两年Niagen Bioscience, Inc.的营收复合增速更高（23.6% vs 1.2%）
Canopy Growth Corp前身为Tweed Marijuana Inc，是一家总部位于加拿大安大略省史密斯福尔斯的大麻企业，在北美大麻行业拥有较高知名度，主要从事大麻相关产品的研发、生产与销售业务。
Niagen Bioscience（原名为ChromaDex）是一家成立于1999年，总部位于加利福尼亚州洛杉矶的生物科技公司。公司业务涵盖标准品、膳食补充剂以及原料技术开发多个领域，目前在纳斯达克挂牌上市。
CGC vs NAGE — 直观对比
营收规模更大
CGC
是对方的1.6倍
$33.8M
营收增速更快
NAGE
高出16.5%
-0.3%
净利率更高
NAGE
高出96.2%
-84.0%
两年增速更快
NAGE
近两年复合增速
1.2%
损益表 — Q3 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $54.4M | $33.8M |
| 净利润 | $-45.7M | $4.1M |
| 毛利率 | 28.8% | 64.1% |
| 营业利润率 | -35.3% | 12.1% |
| 净利率 | -84.0% | 12.2% |
| 营收同比 | -0.3% | 16.2% |
| 净利润同比 | 48.6% | -42.4% |
| 每股收益（稀释后） | — | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CGCNAGE
| Q4 25 | $54.4M | $33.8M | ||
| Q3 25 | $48.7M | $34.0M | ||
| Q2 25 | $52.7M | $31.1M | ||
| Q1 25 | $47.5M | $30.5M | ||
| Q4 24 | $54.6M | $29.1M | ||
| Q3 24 | $46.0M | $25.6M | ||
| Q2 24 | $48.3M | $22.7M | ||
| Q1 24 | $53.1M | $22.2M |
净利润CGCNAGE
| Q4 25 | $-45.7M | $4.1M | ||
| Q3 25 | $-1.2M | $4.6M | ||
| Q2 25 | $-30.3M | $3.6M | ||
| Q1 25 | — | $5.1M | ||
| Q4 24 | $-89.0M | $7.2M | ||
| Q3 24 | $-93.7M | $1.9M | ||
| Q2 24 | $-92.8M | $-15.0K | ||
| Q1 24 | — | $-492.0K |
毛利率CGCNAGE
| Q4 25 | 28.8% | 64.1% | ||
| Q3 25 | 32.8% | 64.5% | ||
| Q2 25 | 25.0% | 65.0% | ||
| Q1 25 | 16.2% | 63.4% | ||
| Q4 24 | 32.2% | 62.5% | ||
| Q3 24 | 34.7% | 63.5% | ||
| Q2 24 | 34.8% | 60.2% | ||
| Q1 24 | 21.3% | 60.7% |
营业利润率CGCNAGE
| Q4 25 | -35.3% | 12.1% | ||
| Q3 25 | -25.3% | 12.5% | ||
| Q2 25 | -31.4% | 10.2% | ||
| Q1 25 | — | 15.7% | ||
| Q4 24 | -31.9% | 24.4% | ||
| Q3 24 | -72.9% | 6.3% | ||
| Q2 24 | -44.0% | -1.1% | ||
| Q1 24 | — | -3.3% |
净利率CGCNAGE
| Q4 25 | -84.0% | 12.2% | ||
| Q3 25 | -2.5% | 13.5% | ||
| Q2 25 | -57.6% | 11.6% | ||
| Q1 25 | — | 16.6% | ||
| Q4 24 | -163.0% | 24.6% | ||
| Q3 24 | -203.7% | 7.3% | ||
| Q2 24 | -192.0% | -0.1% | ||
| Q1 24 | — | -2.2% |
每股收益（稀释后）CGCNAGE
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $0.05 | ||
| Q2 25 | — | $0.04 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $0.02 | ||
| Q2 24 | — | $0.00 | ||
| Q1 24 | — | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $271.1M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $553.5M | $76.5M |
| 总资产 | $807.5M | $106.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CGCNAGE
| Q4 25 | $271.1M | — | ||
| Q3 25 | $217.6M | $64.1M | ||
| Q2 25 | $104.8M | $60.3M | ||
| Q1 25 | $96.0M | $55.5M | ||
| Q4 24 | $130.2M | $44.5M | ||
| Q3 24 | $168.8M | $32.2M | ||
| Q2 24 | $142.3M | $27.7M | ||
| Q1 24 | $148.5M | $27.4M |
股东权益CGCNAGE
| Q4 25 | $553.5M | $76.5M | ||
| Q3 25 | $537.3M | $70.7M | ||
| Q2 25 | $357.0M | $64.2M | ||
| Q1 25 | $355.7M | $55.3M | ||
| Q4 24 | $431.8M | $46.1M | ||
| Q3 24 | $372.1M | $34.4M | ||
| Q2 24 | $389.0M | $30.7M | ||
| Q1 24 | $365.3M | $29.0M |
总资产CGCNAGE
| Q4 25 | $807.5M | $106.4M | ||
| Q3 25 | $781.0M | $98.1M | ||
| Q2 25 | $660.4M | $91.5M | ||
| Q1 25 | $669.9M | $81.3M | ||
| Q4 24 | $849.9M | $68.3M | ||
| Q3 24 | $899.6M | $56.5M | ||
| Q2 24 | $938.9M | $54.0M | ||
| Q1 24 | $949.2M | $54.1M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $679.0K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.16× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CGCNAGE
| Q4 25 | — | $679.0K | ||
| Q3 25 | — | $3.7M | ||
| Q2 25 | $-7.5M | $1.3M | ||
| Q1 25 | $-121.0M | $7.9M | ||
| Q4 24 | — | $8.6M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | $-37.8M | $-264.0K | ||
| Q1 24 | $-205.8M | $295.0K |
自由现金流CGCNAGE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-8.5M | — | ||
| Q1 25 | $-128.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-40.7M | — | ||
| Q1 24 | $-208.3M | — |
自由现金流率CGCNAGE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -16.1% | — | ||
| Q1 25 | -271.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -84.1% | — | ||
| Q1 24 | -392.1% | — |
资本支出强度CGCNAGE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 16.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.9% | — | ||
| Q1 24 | 4.7% | — |
现金转化率CGCNAGE
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | 0.81× | ||
| Q2 25 | — | 0.35× | ||
| Q1 25 | — | 1.56× | ||
| Q4 24 | — | 1.20× | ||
| Q3 24 | — | 1.86× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CGC
| CA | $45.4M | 84% |
| International Markets Cannabis | $6.2M | 11% |
| Other | $1.5M | 3% |
| Other Geographical Area | $1.2M | 2% |
NAGE
| TRUNIAGEN Consumer Product | $27.5M | 81% |
| Ingredients Segment | $5.7M | 17% |
| Other | $694.0K | 2% |
